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Abstract
Background: Novel research has suggested that altered miRNA expression in the placenta is associated with adverse
pregnancy outcomes and with potentially harmful xenobiotic exposures. We hypothesized that aberrant expression of
miRNA in the placenta is associated with fetal growth, a measurable phenotype resulting from a number of intrauterine
factors, and one which is significantly predictive of later life outcomes.
Methodology/Principal Findings: We analyzed 107 primary, term, human placentas for expression of 6 miRNA reported to
be expressed in the placenta and to regulate cell growth and development pathways: miR-16, miR-21, miR-93, miR-135b,
miR-146a, and miR-182. The expression of miR-16 and miR-21 was markedly reduced in infants with the lowest birthweights
(p,0.05). Logistic regression models suggested that low expression of miR-16 in the placenta predicts an over 4-fold
increased odds of small for gestational age (SGA) status (p=0.009, 95% CI=1.42, 12.05). Moreover, having both low miR-16
and low miR-21 expression in the placenta predicts a greater increase in odds for SGA than having just low miR-16 or miR-21
expression (p,0.02), suggesting an additive effect of both of these miRNA.
Conclusions/Significance: Our study is one of the first to investigate placental miRNA expression profiles associated with
birthweight and SGA status. Future research on miRNA whose expression is associated with in utero exposures and markers
of fetal growth is essential for better understanding the epigenetic mechanisms underlying the developmental origins of
health and disease.
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Introduction
Fetal development represents a critical period during which
perturbations to the intrauterine environment through various
factors in the extrauterine environment can have major ramifica-
tions on not only the proper growth and development of the fetus
but also on risk for disease later in life [1]. Barker and Hales [1]
hypothesized that fetuses receive a poor or rich maternal forecast
depending, in part, on the intrauterine and extrauterine conditions
during pregnancy, but that this maternal forecast may not always
accurately predict the post-birth environment and that such
mismatches give rise to disease risk later in life. This has played out
in a number of epidemiologic studies linking low birthweight with
morbidity and mortality in early infancy [2] as well as with an
increased risk for certain diseases later in life, particularly coronary
heart disease, diabetes mellitus type 2, and hypercholesterolemia
[2].
The placenta is of critical importance to ensure the proper
growth and development of the fetus while in utero. It is involved in
providing the fetus with nutrients and is involved in waste and gas
exchange. The placenta’s metabolic activity is crucial for
protecting the fetus from potentially harmful maternal factors
and xenobiotic toxicants that may alter fetal growth and
development. The environment during pregnancy is thought to
impact the appropriate function of the placenta during develop-
ment, thus identification of alterations to the placenta and to
placental gene expression may serve as a record of in utero
exposures and of the intrauterine and extrauterine environments
during pregnancy [3].
The mechanisms by which in utero exposures may dysregulate
the regulatory mechanisms of the placenta continue to be studied.
One mode of alteration may be through the aberrant expression of
microRNA (miRNA), 21–25 nucloeotide long non-coding RNA
involved in post-transcriptional gene regulation [4,5]. miRNA
base-pair to the 39-untranslated region of target mRNA and
effectively silence gene expression by a mechanism of either
translational repression or direct mRNA degradation. The
particular mechanism of this post-transcriptional regulation
depends greatly on the degree of complementarity of the miRNA
to its mRNA target. Previous work has shown that partial
complementarity of a miRNA to an mRNA target may result in
effective repression of translation; therefore, a single miRNA can
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post-transcriptional gene regulation, miRNA have been shown to
regulate a number of key cellular functions including migration,
invasion, growth, and death [6]. miRNA exhibit tissue-specific
expression and function and have been shown to be expressed in
the placenta in addition to a variety of other tissues [7]. Alterations
to placental miRNA expression have been associated with in utero
exposures [8,9] and adverse pregnancy outcomes [10,11,12,13].
Since miRNA have been described as playing important roles in
development and are susceptible to the environment, we sought to
further characterize the expression of six candidate miRNA
previously shown to be expressed in the placenta and previously
reported to target genes in pathways crucial for regulating key cell
processes – miR-16 [9,14], miR-21 [9,15], miR-93 [12,13], miR-
135b [11], miR-146a [9,16], and miR-182 [10] – in a large series of
human placentas for associations with fetal growth.
Results
One hundred seven human placenta samples were analyzed for
the expression of candidate miRNA previously shown to be
expressed in the placenta and involved in regulating cell growth
and developmental processes by targeting genes in a variety of cell
growth and cell functioning pathways, specifically, miR-16, miR-21,
miR-93, miR-135b, miR-146a, and miR-182. The demographics of
the sample population are given in Table 1. Of note, the study
population was oversampled for small for gestational age (SGA)
infants, defined as infants whose birth weight was the lowest 10
th
percentile for their gestational age, calculated as in Fenton [17].
Placentas from SGA neonates comprised approximately 30% of
the study population. Table 2 describes the expression of the 6
candidate miRNA in all of the 107 samples, based on qRT-PCR
and absolute quantification from a standard curve. The range of
expression values differed for the miRNAs, with miR-146a and
miR-182 exhibiting expression in the 0.001–3.95 amol range, while
miR-16 and miR-21 expression was 2 orders of magnitude greater
with expression ranging from 3.53–434.74 amol range. Within
each miRNA, the majority of the samples exhibited relatively
homogenous low levels of expression, but the distributions of
expression exhibited a right skew, suggesting there were still a
number of samples with relatively moderate to high expression. As
these data were not normally distributed, and as we hypothesized
that aberrant high or low expression may be associated with
exposures or outcomes, the expression profiles were split into
quartiles, and birthweight percentile was plotted by quartile of
miRNA expression (Figure 1). Such an analytical strategy using
birthweight percentile as a continuous variable allowed us to gain
a broader observation of association of birthweight percentile with
miRNA expression. Kruskal-Wallis tests were then used to assess
differences in birthweight percentile across quartiles of miRNA
expression (Figure 1). Analysis revealed that birthweight
percentile significantly differed across quartiles of miR-16 and
miR-21 expression, p=0.04 and p=0.02, respectively.
Observing that expression in the lowest quartiles of miR-16 and
miR-21 was associated with reduced birthweight percentile, we
more specifically examined the association between low expression
(#median vs. .median) of the miRNA and infants considered
small for gestational age (SGA), using logistic regression to control
for potential confounders. SGA status served as a more clinically-
relevant marker of the multitude of in utero conditions which may
comprise an adverse intrauterine environment which may be
ultimately associated with low birthweight. These models
(Table 3) demonstrate that low miR-16 expression in the placenta
predicts an odds of 4.13 for SGA (95% CI=1.42, 12.05)
compared to infants with high placenta miR-16 expression,
controlled for confounders. Additionally, low miR-21 expression
in the placenta predicts an intriguing but nonetheless statistically
insignificant, 2.43-fold increased odds for SGA (95% CI=0.93,
6.37) compared to infants with high placenta miR-21 expression
controlled for confounders. Maternal cigarette smoking during
Table 1. Demographics of the study population (n=107).
SGA Non-SGA p
Birthweight, grams, mean (sd) 2501 (326) 3652 (585) ,0.0001
Gestational age, weeks,
mean (sd)
38.7 (1.35) 39.0 (1.07) 0.3
Birthweight by gestational
age status, n (%)
32 (30%) 75 (70%) n/a
Infant gender, n (%) 0.03
Female 23 (72%) 37 (49%)
Male 9 (28%) 38 (51%)
Mode of delivery*, n (%) 0.53
Caesarian section 10 (31%) 29 (39%)
Vaginal delivery 21 (66%) 46 (61%)
Maternal age, years, mean (sd) 28.06 (6.63) 30.04 (5.63) 0.15
Maternal ethnicity**, n (% ) 0.76
Non-white 8 (25%) 16 (21%)
White 24 (75%) 56 (75%)
Maternal cigarette smoking
during pregnancy***
0.01
No 28 (88%) 72 (96%)
Yes 4 (12%) 1 (1%)
Relative weight gained during
pregnancy, % of prepregnancy
weight, mean (sd)****
19.9 (0.09) 21 (0.11) 0.6
Maternal insurance 0.36
Public 15 (47%) 29 (39%)
Private 17 (53%) 46 (61%)
*One sample was missing mode of delivery data.
**Three samples were missing maternal ethnicity data.
***Two samples were missing maternal cigarette smoking during pregnancy
data.
****Two samples were missing weight gained data.
Note: Tests for the difference in specific clinical or demographic factors
between the 2 groups (SGA and non-SGA). T-test was used to examine
differences in continuous variables, and x2-tests for categorical variables.
doi:10.1371/journal.pone.0021210.t001
Table 2. Expression of miR-16, miR-21, miR-93, miR-135b, miR-
146a, and miR-182 determined through qRT-PCR in 107
primary human term placenta samples.
Median (amol) Range (amol)
miR-16 18.64 3.53–399.50
miR-21 54.86 5.25–434.74
miR-93 4.26 0.14–118.39
miR-135b 4.72 0.13–216.92
miR-146a 0.1 0.002–3.95
miR-182 0.23 0.001–3.63
doi:10.1371/journal.pone.0021210.t002
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for growth restriction in both models.
As both miRNA demonstrated independent correlations with
SGA status, we further examined if there was an interaction
between expression of these 2 miRNA in their association with
infant growth outcome. This model (Table 4) demonstrated
that compared to infants having high expression (.median) of
both miRNA, infants with low miR-21 only or low miR-16 only
had non-significant elevation in SGA risk, but infants exhibiting
reduced expression of both miR-16 and miR-21 were significantly
more likely to be classified as SGA (OR 5.38, 95% CI 1.52,
19.01). Although a likelihood ratio test suggested no significant
multiplicative interaction between miR-16 and miR-21 (p.0.05),
there was a significant trend for increased risk of being classified
as SGA from having only miR-21 reduced or only miR-16
reduced in expression to having both reduced in expression
(p,0.02).
Previous work has empirically validated PTEN as a target of
miR-21 in a variety of cancers [18,19]. We overexpressed miR-21
in TCL-1 placental cells, a third trimester human placental cell
line, and used Western blot to assess PTEN protein levels in cells
overexpressing miR-21 versus cells transfected with negative
control. Cells overexpressing miR-21 had approximately 50% less
PTEN protein relative to tubulin than cells transfected with
negative control (Figure 2), suggesting that PTEN is a target of
miR-21 in TCL-1 cells.
Discussion
We have demonstrated the expression of key candidate
miRNA in a large, population-based series of primary human
placenta samples and their association with poor fetal growth,
specifically identifying that reduced expression of miR-16 and
miR-21 are significantly associated with growth restriction. A
number of groups have previously described placental miRNA
expression associations with maternal conditions such as
preeclampsia [10], with maternal cigarette smoking during
pregnancy [20], and as markers of pregnancy itself [11].
Furthermore, more is being uncovered about the role of miR-16
and miR-21 in regulating key cellular processes, especially the
Figure 1. Distribution of infant birthweights (y-axis) by primary term human placenta miRNA expression quartiles (x-axis). (A) miR-16
(p=0.04), (B) miR-21 (p=0.02), (C) miR-93 (p=0.88), (D) miR-135b (p=0.84), (E) miR-146a (p=0.46), and (F) miR-182 (p=0.55). Black bars indicate
median of birthweight percentile within each quartile. Kruskal-Wallis tests revealed that birthweight percentile significantly differed across quartiles
of miR-16 and miR-21 expression (p,0.05).
doi:10.1371/journal.pone.0021210.g001
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and miR-21’s capability of regulating cell cycling and cell
proliferation [15].
Differences in birthweight percentile were examined across
quartiles of miRNA expression (Figure 1). Birthweight percentile
significantly differed across quartiles of miR-16 and miR-21
expression, p=0.04 and p=0.02, respectively. Further analysis
revealed that Q2, the moderate-low expression of miR-16 and miR-
21, was especially associated with lower birthweight percentile; this
is an intriguing observation possibly suggesting that the moderate-
low expression of miR-16 and miR-21 associated with lower
birthweight percentiles more than the extreme low expression of
miR-16 and miR-21. These data suggest that lower expression of
miR-16 and miR-21 in placenta does associate with lower
birthweight percentiles but that the moderate-low expression of
these miRNA in placenta may be particularly associative with
reduced birthweight; such an observation merits further investi-
gation in the future.
miR-21 has been described as an oncogene, plays a role in
enhancing tumor phenotypes including proliferation and migra-
tion, and has been shown to target a number of key regulators
of these processes, including but not limited to PLAG1 [21] and
PTEN [18,19]. Meng and coworkers showed that miR-21
regulates PTEN in human hepatocellular cancer [19], and
Lou and colleagues demonstrated that in ovarian epithelial
carcinomas, miR-21 promotes proliferation, invasion and migra-
tion abilities by inhibiting PTEN [18]. Previous work has
demonstrated that PTEN is expressed in the placenta under
normal conditions and may have expression profiles which differ
associated with pregnancy stage [22]. Our proof-of-principle
data suggest that TCL-1 placental cells overexpressing miR-21
have approximately 50% less PTEN protein than cells
transfected with negative control, suggesting that PTEN may
be a target of miR-21 in TCL-1 cells. As the function of the
placenta, though, is to promote fetal growth through its own
proliferation and invasion into the maternal decidua, downreg-
ulation of miR-21 in the placenta could, through dysregulation of
PTEN, result in decreased invasion of the maternal decidua,
decreased migration, and decreased growth – the opposite of
what has been observed to occur in the case of upregulated miR-
21 [19].
As with many miRNA, miR-16 exhibits tissue-specific function
and expression. In a number of cancer cell lines, miR-16 has
been shown to be involved in the induction of apoptosis by
targeting BCL-2 [23] and in cell cycle regulation by targeting
CDK6 [24], CDC27 [25], and CARD10 [26]. In other cell
types, miR-16 has different functions, such as targeting HMGA1
and Caprin-1 [27], further suggesting that miR-16 may have
cell-type function and expression [23,27]. Dysregulation of miR-
16 in the placenta may lead to aberrant expression of its targets
and may lead to functional and developmental abnormalities in
the placenta that might result in reduced infant birthweight.
Mechanistic research using model systems is needed to further
elucidate the pathways regulated by miR-16 and miR-21 and to
better determine the functional consequence of downregulation
of miR-16 and miR-21 in the placenta. Additionally, more work
to determine the functional effects of miRNA crosstalk – that is,
miRNAs whose differential expression may have additive
Table 3. Logistic regression for the association between individual miRNA expression and SGA status.
Effect Odds Ratio 95% Wald Confidence Limits p
miR-16 Expression in Placenta, n (%)
High n=52 (51%) Reference
Low n=50 (49%) 4.13 1.42–12.05 0.009
Maternal Smoking During Pregnancy, n (%)
No n=97 (95%) Reference
Yes n=5 (5%) 22.18 1.72–286.86 0.018
Effect Odds Ratio 95% Wald Confidence Limits p
miR-21 Expression in Placenta, n (%)
High n=52 (51%) Reference
Low n=50 (49%) 2.43 0.93–6.37 0.069
Maternal Smoking During Pregnancy, n (%)
No n=97 (95%) Reference
Yes n=5 (5%) 10.82 0.82–143.58 0.071
Also included in models: Relative Weight Gained During Pregnancy, Maternal Ethnicity, Maternal Age, Delivery Method, Insurance, and Infant Gender.
Samples lacking one or more piece of covariate data were excluded from the model.
doi:10.1371/journal.pone.0021210.t003
Table 4. Logistic regression to examine the interaction of low
miR-16 and low miR-21 expression on the association with
SGA status.
Effect Odds Ratio
95% Wald
Confidence Limits
miR-21 and miR-16, n (%)
Both High, n=36 (35%) Reference
Low miR-21 only, n=16 (16%) 1.54 0.29–8.21
Low miR-16 only, n=16 (16%) 3.35 0.69–16.32
Both Low, n=34 (33%) 5.38 1.52–19.01
Also included in model: Relative Weight Gained During Pregnancy, Maternal
Ethnicity, Maternal Age, Delivery Method, Insurance, and Infant Gender.
p for trend (p,0.02).
Samples lacking one or more piece of covariate data were excluded from the
model.
doi:10.1371/journal.pone.0021210.t004
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necessary to better understand the complex regulatory networks
involved.
Poor fetal growth associated with adverse intrauterine
conditions continues to be characterized. Infants classified as
small for gestational age (SGA) may have experienced a number
of heterogeneous environmental and placental conditions
associated with describe the complex phenotype that is SGA.
Because of the complexity of the conditions that may be
associated with SGA status, we used SGA status as a marker
suggestive of the complex milieu of conditions that may be
associated with small fetal growth. Fetal malnutrition linked to
growth restriction has been shown occur in a variety of
conditions, including but not limited to poverty, pregnancy in
women with eating disorders, and pregnancy in high altitude
[28]. Maternal cigarette smoking during pregnancy is associated
with an increased risk of fetal growth restriction [29,30], and
exposure to environmental toxicants in utero, such as those found
in cigarette smoke, is associated with increased placental
aberrations [31] and decreased placental function [32]. Previous
work in our lab has suggested that maternal cigarette smoking
during pregnancy is associated with the downregulation of miR-
16, miR-21, and miR-146a in the placenta [9]. Thus, maternal
cigarette smoking during pregnancy was included in our
multivariable linear regression models because of its status as a
potential confounder due to its associations with both reduced
birthweight as well as reduced placental miRNA expression. A
number of animal models have been generated to further study
low birthweight in a controlled, experimental system [30,33],
and it will be important to consider the role of miRNA in these
animal models. Because poor maternal forecasts leading to low
birthweight may not accurately predict the post-birth environ-
ment and because low birthweight increases one’s risk for a
number of diseases later in life [2], more research is necessary to
more fully understand the pathways whose dysregulation may
ultimately affect birthweight.
As described described above, the multitude of factors that may
contribute to altered fetal growth contribute to the relative
complexity of the intrauterine environment. As concluded by Avila
et al., site-to-site variability of gene expression does exist in the
human placenta [34], and thus it was important for us to collect
biopsies from a number of sites within each placenta sample. Since
the 12 biopsies of placenta were then homogenized and combined
following homogenization and prior to further analysis, we would
argue that exact location within the placenta would not likely
contribute to the variation in miRNA expression across the 107
placentas. A more extensive analysis of placental cell type would
be important for determining differences in miRNA expression
among cell types but is currently beyond the scope of our current
work.
Mouillet and colleagues published important work investigating
circulating levels of a set of trophoblast miRNA found in plasma
and their association with fetal growth [12]. Their work was an
important step in determining associations of differential miRNA
expression present in plasma with fetal growth restriction. While
similar in overall hypothesis, namely, that a subset of miRNA may
be associated with fetal growth, our study and the work by
Mouillet and colleagues differed in the sampling site, the number
of samples utilized, and the candidate miRNA investigated. Our
study utilized samples taken directly from term human placenta
while Mouillet and colleagues used plasma samples containing
circulating trophoblast miRNA. Additionally, Mouillet and
coauthors’ sample set contained far fewer samples than ours. In
addition, we provided covariate data that Mouillet and coauthors
did not. While it may indeed prove to be of important clinical
utility to be able to utilize plasma samples containing circulating
miRNA for future tests investigating pregnancy stage, exposure, or
even fetal growth, our work was different in that we specifically
were interested in characterizing miRNA expression in placentas
which may be associated with aberrant fetal growth. Furthermore,
we investigated miRNA expression in term placentas which may
serve as a record of the complex intrauterine environment capable
of programming the fetus positively or negatively. Both our work
and the work of Mouillet and colleagues are important steps in
further examining associations of miRNA expression with altered
fetal growth.
In summary, our data suggesting that low expression of miR-16
and miR-21 in the placenta is associated with poor fetal growth
may have many important implications. Our data are an
important step in discovering miRNA expression profiles associ-
ated with low birthweight which may be powerful predictors of risk
for disease later in life, such as coronary heart disease, diabetes,
and hypercholesterolemia. This study is an important stepping
stone in that it establishes that miRNA have the potential to
predict future health outcomes based, in part, on their altered
expression in the placentas of low birthweight infants. More work
is needed to investigate how particular insults to the fetal
environment may associate with alterations to placental miRNA
expression and how these aberrant expression profiles may be
associated with differential fetal growth. Future work to determine
the roles of miRNA in specific pathways leading to altered fetal
growth will be key to better understanding fetal growth as both a
marker of the intrauterine environment as well as a developmental
outcome and in better comprehending the developmental origins
of health and disease.
Figure 2. TCL-1 cells overexpressing miR-21 express approxi-
mately 50% less PTEN protein than TCL-1 cells transfected with
negative control (p,0.05).
doi:10.1371/journal.pone.0021210.g002
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Ethics statement/Placenta samples
All placenta samples used were collected as part of the Rhode
Island Child Health Study (RICHS), an ongoing, population-
based birth cohort at Women and Infants’ Hospital in
Providence, RI. The ongoing Rhode Island Child Health Study
enrolls mother-infant pairs following delivery at Women and
Infants Hospital in Providence, Rhode Island, USA. Term
infants born small for gestational age (SGA, lowest 10
th
percentile) based on birthweight and gestational age and
calculated from the Fenton growth chart [17] were selected,
and an appropriate for gestational age infant matched on infant
gender, gestational age (63 days), and maternal age (62y e a r s )
is also enrolled. Only singleton, viable infants are included in the
study. Other exclusion criteria are maternal age ,18 years or a
life-threatening medical complication in the mother, and
congenital or chromosomal abnormality of the infant. A
structured chart review was used to collect information from
the maternal inpatient medical record from delivery, and
mothers were subjected to an interviewer-administered struc-
tured questionnaire to obtain information on the lifestyle,
demographics, and exposure histories of the participants. All
study participants provided informed consent. For each placenta
collected, 12 biopsies of placenta tissue, 3 from each of 4
quadrants (totaling approximately 1 g of tissue) were excised,
from the maternal side of the placenta 2 cm from the umbilical
cord insertion site, free of maternal decidua. The samples were
placed immediately in RNAlater and stored at 4uC. At least
72 hours later, the 12 placenta biopsies were removed from
RNAlater, blotted dry, snap-frozen in liquid nitrogen, homog-
enized using a mortar and pestle, combined to make one
homogenized sample per placenta, and stored in sample tubes at
280uC until needed for examination. A structured chart review
was used to collect information from the maternal inpatient
medical record from delivery, and mothers were subjected to an
interviewer-administered structured questionnaire to obtain
information on the lifestyle, demographics, and exposure
histories of the participants. All samples and information were
collected under appropriate protocols approved by the Institu-
tional Review Boards for Women and Infants’ Hospital and
Brown University.
RNA extraction
RNA was extracted from placenta samples and cultured cells
using the miRvana miRNA Isolation Kit (Ambion) and manufac-
turer protocols as described previously [20]. For tissue samples,
200 mg of homogenized tissue was used for extraction. Extracted
RNA was quantified using a Nanodrop spectrophotometer and
then aliquoted into single-use aliquots and stored at 280uC.
Quantitative RT-PCR (qRT-PCR) for mature miRNA
Expression of mature miRNAs was measured using commer-
cially available TaqMan microRNA Assays or TaqMan Gene
Expression Assays (Applied Biosystems, Valencia, CA) on an
Applied Biosystems 7900HT Real-Time PCR system and
analyzed with 7900HT System Software. Absolute quantitation
of miRNA was calculated using a standard curve generated from
serial dilutions of miRNA-specific pre-miR oligonucleotides
(Ambion) run on each plate for each miRNA of interest, as
previously described for array analyses by Bissels and colleagues
[35]. All reactions were run in triplicate on 384-well plates, and
RNU-44 was used as an internal control for each sample to assess
sample performance. No-RT controls were also run for each
sample on each plate to assure samples were free of genomic
DNA.
Cell culture and transfection
TCL-1 placental cells were cultured as described previously [9].
Placental cells were transfected using the pre-miR miRNA
precursors (Ambion) system and siPORT NeoFX transfection
agenet (Ambion) following manufacturer’s protocols.
Western blot
Western blots were used to confirm that overexpression of
miR-21 resulted in decreased protein levels of PTEN compared
to cells transfected with negative control. Following cell harvest
and lysate collection, total protein was quantified using the BCA
assay (Thermo Scientific) and manufacturer protocols. Cell
lysates were then separated electrophoretically using 10% Tris-
HCl gels (Bio-Rad). Proteins were transferred to Immuno-Blot
PVDF membranes (Bio-Rad) through overnight night transfer at
4 degrees C and following transfer, membranes were washed
with TBSt (Boston Bioproducts) and blocked with 5% milk in
TBSt. For Western blot analysis, antibodies against PTEN
(Invitrogen) and gamma-Tubulin (Cell Signaling) were used to
visualize corresponding proteins following established protocols
for staining and washing. Proteins were visualized using the
Amersham ECL Western Blotting Analysis System (GE
Healthcare) following the manusfacturer’s protocol. Resulting
images were scanned and protein quantitation was performed
using Image J software.
Statistical analysis
Birthweight percentile was calculated using the Fenton growth
chart [17]. SGA was defined as the lowest 10% of birthweight
percentile, as described previously by Fenton [17]. Kruskal-Wallis
tests were used to determine if birthweight percentile significantly
differed across quartiles of miRNA expression. Logistic regression
models were used to analyze if differential expression of miRNA
predicted increased risk for SGA while also considering potential
confounders. All analyses were conducted in SAS 9.2 (SAS
Institute, Cary, NC). Student’s t-tests were used to determine if
overexpression of candidate miRNA resulted in differential protein
levels as determined by densitometry of PTEN and tubulin.
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